1415792-84-5 ((Sovleplenib)

Sovleplenib;9CL6353KHO;Pyrido[3,4-b]pyrazin-5-amine, 7-[4-[1-(methylsulfonyl)-4-piperidinyl]phenyl]-N-[(2S)-2-morpholinylmethyl]-;Sovleplenib [INN];GTPL11886;compound 225 [WO2012167733A1];(S)-7-(4-(1-(Methylsulfonyl)piperidin-4-yl)phenyl)-N-(morpholin-2-ylmethyl)pyrido(4,3-b)pyrazin-5-amine;1415792-84-5;(S)-7-(4-(1-(METHYLSULFONYL)PIPERIDIN-4-YL)PHENYL)-N-(MORPHOLIN-2-YLMETHYL)PYRIDO[3,4-B]PYRAZIN-5-AMINE;Sovleplenib [WHO-DD];HY-145598;MS-28979;Sovleplenib (USAN/INN);CS-0376654;SCHEMBL14242080;Spleen Tyrosine Kinase Inhibitor HMPL-523;EX-A7664;Syk Inhibitor HMPL-523;DA-67702;AKOS040752025;7-[4-(1-methylsulfonylpiperidin-4-yl)phenyl]-N-[[(2S)-morpholin-2-yl]methyl]pyrido[3,4-b]pyrazin-5-amine;F78019;D12953;HMPL-523;compound 225 (WO2012167733A1);UNII-9CL6353KHO;HMPL-523 [WHO-DD];GLXC-27900;HMPL523;

NJIAKNWTIVDSDA-FQEVSTJZSA-N

1S/C24H30N6O3S/c1-34(31,32)30-11-6-18(7-12-30)17-2-4-19(5-3-17)21-14-22-23(27-9-8-26-22)24(29-21)28-16-20-15-25-10-13-33-20/h2-5,8-9,14,18,20,25H,6-7,10-13,15-16H2,1H3,(H,28,29)/t20-/m0/s1

S(C)(N1CCC(C2C=CC(C3C=C4C(=C(N=3)NC[C@@H]3CNCCO3)N=CC=N4)=CC=2)CC1)(=O)=O